What is the role of fondaparinux (Arixtra) in the treatment of acute coronary syndrome (ACS)?

Updated: Sep 30, 2020
  • Author: David L Coven, MD, PhD; Chief Editor: Eric H Yang, MD  more...
  • Print
Answer

Another factor Xda inhibitor, fondaparinux (Arixtra), has been studied for use in patients with STEMI who do not undergo PCI. [97] In the Fifth Organization to Assess Strategies in Ischemic Syndromes (OASIS-5) trial, fondaparinux reduced major bleeding and improved net clinical outcome compared with enoxaparin in patients receiving GP IIb/IIIa inhibitors or thienopyridines for ACS. [98] Fondaparinux is not currently FDA approved for use in ACS.


Did this answer your question?
Additional feedback? (Optional)
Thank you for your feedback!